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Summary Classic hairy cell leukemia (HCL) is a rare
indolent B-cell-lymphoproliferative disorder, first de-
scribed as a distinct disease entity in 1958. After more
than two decades without effective chemotherapeutic
options and a dismal prognosis of less than 5 years,
only the introduction of interferon-α (IFN-α) allowed
for response rates between 80–90% and survival im-
provement. Nowadays, however, patients are rarely
treated with IFN-α as purine analogues were found to
be highly effective in HCL facilitating a near normal
life span in most cases. Moreover, novel therapeutic
tools for patients with relapsed or refractory disease
after purine analogues have emerged such as ritux-
imab and, more recently, vemurafenib. In the absence
of long-term safety data for these novel agents, how-
ever, IFN-α may still represent a viable therapeutic
option when the profound immunosuppressive side
effects of purine analogues are to be avoided. We
herein report a HCL patient, who has received multi-
ple lines of therapy, including pentostatin, cladribine,
and a total of 164 months of treatment with IFN-α
yielding long-term disease control. Our case illus-
trates that long-term administration of IFN-α with
adequate dose-adjustments according to toxicity and
disease activity is feasible in HCL and may still be
a viable therapeutic option when purine analogues
are considered unsuitable.
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Introduction
Classic hairy cell leukemia (HCL) is a rare indolent
B-cell lymphoproliferative disorder. First described as
a distinct disease entity by Bouroncle et al. in 1958,
HCL inherited a dismal survival prognosis of less than
5 years [1]. In the absence of effective systemic ther-
apeutic options splenectomy was treatment of choice
for decades, only allowing for short-lived remissions
[2]. The first substantial therapeutic intervention in
this previously “untreatable” chronic leukemia was
made with the introduction of interferon-α (IFN-α)
in 1984 with response rates of 80–90% (≤90% par-
tial remissions, PR; ≤40% complete remissions, CR)
and extension in survival [3–6]. Only shortly there-
after, however, HCL was found to be highly sensitive
for purine analogues, an observation that rapidly al-
tered the natural history of HCL. Facilitating a near
normal life span in the majority of patients, purine
analogues have become first line therapy for HCL [7,
8]. Inferior in terms of quality and duration of re-
sponse, nowadays IFN-α is rarely treatment of choice.
Moreover, novel therapeutic tools for patients with
relapsed or refractory disease after purine analogues
have emerged such as rituximab and, more recently,
vemurafenib [9–13]. In the absence of long-term
safety data for these novel agents, however, induction
and maintenance therapy with IFN-α may still repre-
sent a viable therapeutic option when the profound
immunosuppressive side effects of purine analogues
are to be avoided, e. g., in the presence of significant
comorbid conditions and ongoing infectious compli-
cations. We herein report a HCL patient, who has
received multiple lines of therapy, including pento-
statin, cladribine, and a total of 164 months of treat-
ment with IFN-α yielding long-term disease control
(Table 1).
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Table 1 Clinical outcomeof consecutive treatments inourHCLpatient
Line of treat-
ment





1 Splenectomy – 05/1982 – PR 12 months None
2 Interferon-α 1.5 × 106 U/week 06/1983–
06/1986
36 months PR 36 months None
3 Pentostatin 4 mg/m² 07/1986–
03/1987




4 Interferon-α 4.5–9 × 106 U/week 01/2000–
11/2007
95 months PR 95 months None




6 Interferon-α 4.5 × 106 U/week 12/2011–
08/2014
33 months PR 33 months None
CR complete remission. A complete remission was defined as the morphological absence of hairy cells in blood and bone marrow in combination with complete
resolution of cytopenia and organomegaly
PR partial remission. A partial remission was defined as a complete resolution of cytopenia in combination with at least 50% decrease in organomegaly and
hairy cell infiltration of the bone marrow
a4 mg/m² per week x3, then every other week x3, then once monthly x6
Case report
The now 80-year-old female patient was diagnosed
with HCL at the age of 47 years and treated with
elective splenectomy. One year later, she required
systemic therapy and received IFN-α induction treat-
ment for 3 months resulting in a PR with residual
bone marrow infiltration, which was maintained over
3 years (1.5 × 106 U/week). At the age of 51, the
patient was switched to pentostatin resulting in a CR
and a progression-free survival (PFS) of 13 years.
Due to recurrent serious infectious complications
after treatment with pentostatin (febrile neutrope-
nia, urinary tract infections, pneumonias) she was
considered unsuitable for further purine analogue
treatment. Hence, she again received IFN-α for the
next 95 months at varying dosages adjusted according
to toxicity and disease activity (4.5–9 × 106 U/week)
resulting in a CR. Bone marrow biopsy showed only
minimal infiltration (<0.5%) by hairy cells after 2 years
on IFN-α. Nevertheless, IFN-α was stopped due to
persisting side-effects, mostly flu-like symptoms and
fatigue. Therefore, she received cladribine resulting
in a CR of 49 months, but also in prolonged pancy-
topenia complicated by recurrent infections (febrile
neutropenia, urinary tract infections). Thus, when the
next line of treatment was necessary, the now 76-year-
old patient preferred IFN-α (4.5 × 106 U/week) over
purine analogues, resulting in a sustained disease
control with fully compensated blood counts but per-
sistent hairy cells in peripheral blood for 33 months.
Altogether, our patient has received IFN-α treatment
cumulatively for almost 14 years. Long-term disease
control was achievable, even after pretreatment with
purine analogues. Besides recurrent flu-like symp-
toms and fatigue, no severe adverse advents such as
autoimmune phenomena and no secondary malig-
nancies were observed.
Discussion
Purine analogues are highly effective in HCL andmore
convenient to patients than IFN-α considering the sin-
gle cycle of therapy needed to achieve a durable CR in
most cases [7]. However, treatment with purine ana-
logues is often accompanied by severe myelotoxicity,
which cumulates with each further cycle of therapy
necessary at relapse possibly leading to significant in-
fectious complications. The use of IFN-α in HCL is
not commonly associated with severe adverse events,
but the CR rates achievable are low and relapse seems
inevitable after cessation of the drug [8]. Neverthe-
less, two small retrospective studies suggest that in-
duction therapy with IFN-α followed by maintenance
until disease progression may be of more durable ef-
ficacy and result in longer PFS. Long-term tolerability
was achievable with only a minority of patients expe-
riencing dose-limiting side effects, which prevented
further drug administration [14, 15]. Notably, in pre-
viously untreated HCL patients evenminimal doses of
IFN-α have been shown to be clinically effective and
almost free of toxicity [16].
These findings also gain more timeliness in view of
novel treatment options provided for HCL patients.
As HCL strongly expresses CD20 [17], rituximab has
demonstrated efficacy with response rates of 25–80%
in relapsed or refractory patients [9–12]. As IFN-α,
however, rituximab is inferior to purine analogues
with regard to quality and duration of response and
there is no data about maintenance therapy. More-
over, anti-CD20 antibodies may also cause further
immunosuppression as well as infusion related reac-
tions [18].
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More recently, the usage of vemurafenib demon-
strated efficacy in 50 relapsed or refractory HCL pa-
tients with confirmed BRAF V600E mutation status
[13]. In the absence of clinically significant myelotox-
icity, vemurafenib was suggested an adequate thera-
peutic option in patients with cumulative myelotoxic-
ity due to previous chemotherapies. However, disease
progression is frequently observed after cessation of
the drug as residual leukemic cells may persist under
vemurafenib treatment. Moreover, 14% of patients
experienced secondary skin tumors despite the limi-
tation of vemurafenib administration to 16–18 weeks.
Notably, even low-dose vemurafenib may increase the
risk of secondary cancers when given continuously
[19].
Our HCL patient with recurrent severe infectious
complications after purine analogues eventually
achieved long-term disease control with IFN-α at
varying dosages adjusted to toxicity and disease activ-
ity for a total of 164 months. Treatment interruptions
resulted in rapid relapses, but the patient remained
drug-sensitive despite three courses of IFN-α with
total treatment duration of nearly 14 years. With
a follow-up of 33 years, no cumulative toxicity and
in particular no secondary malignancies— a finding
in HCL patients reported to be related to (repeated)
purine analogue treatments—have been observed
[20].
Despite the novel tools emerged in the treatment
of HCL, our case illustrates that long-term adminis-
tration of IFN-α with adequate dose-adjustments ac-
cording to toxicity and disease activity is feasible and
may still be a viable therapeutic option when purine
analogues are considered unsuitable.
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